Literature DB >> 16973174

Effective engraftment but poor mid-term persistence of mononuclear and mesenchymal bone marrow cells in acute and chronic rat myocardial infarction.

Jochen Müller-Ehmsen1, Benjamin Krausgrill, Volker Burst, Kerstin Schenk, Uta C Neisen, Jochen W U Fries, Bernd K Fleischmann, Jürgen Hescheler, Robert H G Schwinger.   

Abstract

Bone marrow cells are used with promising results for cell therapy after myocardial infarction (MI). We determined the survival and organ distribution of transplanted mononuclear (MNC) or mesenchymal (MSC) bone marrow cells, and the influence of cell type, cell number and application time. MNC and MSC (male Fischer 344 rats) were injected into the border zone of MI (syngeneic females) immediately or 7 days after LAD ligation (10(5) or 10(6) cells, 50 microl). After 0 h, 48 h, 5 days, 3 weeks and 6 weeks, DNA of heart, lung, liver, spleen, kidney, blood, bone marrow, brain and skeletal muscle was isolated and the number of donor cells determined by quantitative real-time PCR with Y-chromosome specific primers (each n>or=4). The percentage of donor-cells in the heart decreased rapidly from 34-80% of injected cells (0 h) to 0.3-3.5% (6 weeks) independent from cell type, number and application time. The absolute number increased after increasing injected cell number (10(6) vs. 10(5)). In the lung, MNC and MSC were found at 0 h (126+/-48 and 140+/-3 per million organ cells), but in liver and kidney, only few. At 48 h and 6 weeks, an increasing number of MNC, but not MSC, were detected in the spleen (6 weeks, 602+/-173 per million organ cells vs. 95+/-50 in the heart, P=0.02). In all other organs, only few or no grafted cells of either cell type were detected at these times. Organ distribution was independent from injection time. The low survival of grafted cells may limit their therapeutic impact, while their distribution to other organs must be considered in all cell therapy applications.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16973174     DOI: 10.1016/j.yjmcc.2006.07.023

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  75 in total

Review 1.  Protein localization in the plant Golgi apparatus and the trans-Golgi network.

Authors:  C Saint-Jore-Dupas; V Gomord; N Paris
Journal:  Cell Mol Life Sci       Date:  2004-01       Impact factor: 9.261

Review 2.  Cardiac cell therapy: boosting mesenchymal stem cells effects.

Authors:  E Samper; A Diez-Juan; J A Montero; P Sepúlveda
Journal:  Stem Cell Rev Rep       Date:  2013-06       Impact factor: 5.739

3.  Progenitor cells isolated from the human heart: a potential cell source for regenerative therapy.

Authors:  P van Vliet; M Roccio; A M Smits; A A M van Oorschot; C H G Metz; T A B van Veen; J P G Sluijter; P A Doevendans; M-J Goumans
Journal:  Neth Heart J       Date:  2008-05       Impact factor: 2.380

4.  Human embryonic stem cell-derived mesenchymal stromal cell transplantation in a rat hind limb injury model.

Authors:  Juha P Laurila; Lilja Laatikainen; Maria D Castellone; Parul Trivedi; Jari Heikkila; Ari Hinkkanen; Peiman Hematti; Mikko O Laukkanen
Journal:  Cytotherapy       Date:  2009       Impact factor: 5.414

5.  In-vivo comparison of the acute retention of stem cell derivatives and fibroblasts after intramyocardial transplantation in the mouse model.

Authors:  Cajetan Lang; Sebastian Lehner; Andrei Todica; Guido Boening; Mathias Zacherl; Wolfgang-Michael Franz; Bernd Joachim Krause; Peter Bartenstein; Marcus Hacker; Robert David
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-07-26       Impact factor: 9.236

6.  Evaluation of Simvastatin and Bone Marrow-Derived Mesenchymal Stem Cell Combination Therapy on Airway Remodeling in a Mouse Asthma Model.

Authors:  Maryam Mohammadian; Hamid Reza Sadeghipour; Iraj Ragerdi Kashani; Gila Pirzad Jahromi; Amene Omidi; Amir Kavian Nejad; Ravie Golchoobian; Mohammad Hossein Boskabady
Journal:  Lung       Date:  2016-05-09       Impact factor: 2.584

7.  Dual angiogenic and neurotrophic effects of bone marrow-derived endothelial progenitor cells on diabetic neuropathy.

Authors:  Jin-Ok Jeong; Mee-Ohk Kim; Hyongbum Kim; Min-Young Lee; Sung-Whan Kim; Masaaki Ii; Jung-uek Lee; Jiyoon Lee; Yong Jin Choi; Hyun-Jai Cho; Namho Lee; Marcy Silver; Andrea Wecker; Dong-Wook Kim; Young-sup Yoon
Journal:  Circulation       Date:  2009-01-26       Impact factor: 29.690

8.  Comparison of transplantation of adipose tissue- and bone marrow-derived mesenchymal stem cells in the infarcted heart.

Authors:  Koen E A van der Bogt; Sonja Schrepfer; Jin Yu; Ahmad Y Sheikh; Grant Hoyt; Johannes A Govaert; Jeffrey B Velotta; Christopher H Contag; Robert C Robbins; Joseph C Wu
Journal:  Transplantation       Date:  2009-03-15       Impact factor: 4.939

9.  Comparison of different adult stem cell types for treatment of myocardial ischemia.

Authors:  Koen E A van der Bogt; Ahmad Y Sheikh; Sonja Schrepfer; Grant Hoyt; Feng Cao; Katherine J Ransohoff; Rutger-Jan Swijnenburg; Jeremy Pearl; Andrew Lee; Michael Fischbein; Christopher H Contag; Robert C Robbins; Joseph C Wu
Journal:  Circulation       Date:  2008-09-30       Impact factor: 29.690

10.  Lipopolysaccharide preconditioning enhances the efficacy of mesenchymal stem cells transplantation in a rat model of acute myocardial infarction.

Authors:  Yongwei Yao; Fumin Zhang; Liansheng Wang; Guohui Zhang; Zhaojun Wang; Jianmei Chen; Xiang Gao
Journal:  J Biomed Sci       Date:  2009-08-20       Impact factor: 8.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.